5-HT1D receptor

5-HT1D receptor is a serotonin receptor that is encoded by the HTR1D gene in humans. It is a subtype of the 5-HT1 receptor that binds to the neurotransmitter serotonin, also known as 5-hydroxytryptamine (5-HT). The 5-HT1D receptor plays a significant role in the central nervous system (CNS) and is involved in various physiological processes.

Function[edit | edit source]

The 5-HT1D receptor is primarily found in the brain, particularly in the basal ganglia, hippocampus, and cerebral cortex. It is involved in the regulation of serotonin release, which influences various physiological processes such as mood, appetite, and sleep. The 5-HT1D receptor also plays a role in the constriction of blood vessels and the inhibition of neurotransmitter release in the brain.

Clinical significance[edit | edit source]

The 5-HT1D receptor is a target for the treatment of migraines. Triptans, a class of drugs used to treat migraines, work by activating the 5-HT1D receptor, which results in the constriction of blood vessels in the brain and the inhibition of pro-inflammatory neuropeptide release.

In addition, the 5-HT1D receptor is implicated in psychiatric disorders such as depression and anxiety. Some antidepressants and anxiolytics work by modulating the activity of the 5-HT1D receptor.

Ligands[edit | edit source]

Several ligands bind to the 5-HT1D receptor, including both agonists and antagonists. Agonists increase the activity of the receptor, while antagonists decrease its activity. Some of the most commonly used 5-HT1D receptor ligands in research and clinical practice include sumatriptan, zolmitriptan, and naratriptan, all of which are agonists.

See also[edit | edit source]

Template:GPCR-stub Template:Serotonin receptor agonists and antagonists

5-HT1D receptor Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.